INFLUVAC TETRA 15 MCG / 0.5 ML — DIN 02484854
HAEMAGGLUTININ-STRAIN A (H1N1) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN B (YAMAGATA) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN B (VICTORIA) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN A (H3N2) : 15 MCG / 0.5 ML · BGP PHARMA ULC · SUSPENSION · wholesale supply in Canada
Health Canada status: MARKETED
What is INFLUVAC TETRA?
INFLUVAC TETRA 15 MCG / 0.5 ML contains HAEMAGGLUTININ-STRAIN A (H1N1) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN B (YAMAGATA) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN B (VICTORIA) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN A (H3N2) : 15 MCG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02484854, held by BGP PHARMA ULC, supplied as SUSPENSION for SUBCUTANEOUS ; INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 17-Oct-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is INFLUVAC TETRA used for?
Prevention of influenza infection caused by the specific strains contained in the vaccine, in adults and children from 6 months of age and older.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Influenza, Inactivated, Split Virus Or Surface Antigen in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
8 holders have a Canadian DIN containing Influenza, Inactivated, Split Virus Or Surface Antigen, across 36 DINs, of which 8 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SANOFI PASTEUR LIMITED | 15 | 3 | FLUZONE, FLUZONE HIGH-DOSE, FLUZONE HIGH-DOSE QUADRIVALENT, FLUZONE QUADRIVALENT, FLUZONE TRIVALENT SUBVIRION, +4 more | Sourceable in Canada |
| SEQIRUS UK LIMITED | 8 | 2 | AGRIFLU, FLUAD, FLUAD PEDIATRIC, FLUCELVAX, FLUCELVAX QUAD | Sourceable in Canada |
| ID BIOMEDICAL CORPORATION OF QUEBEC | 5 | 2 | AREPANRIX H5N1, FLULAVAL TETRA, FLUVIRAL, INFLUENZA A (H1N1) 2009 PANDEMIC MONOVALENT VACCINE (WITHOUT ADJUVANT) | Sourceable in Canada |
| BGP PHARMA ULC | 1 | 1 | INFLUVAC TETRA | Sourceable in Canada |
| SANOFI PASTEUR INC | 2 | 0 | FLUZONE | No marketed DIN |
| SEQIRUS PTY LTD | 2 | 0 | AFLURIA TETRA | No marketed DIN |
| SEQIRUS UK LIMITED 29 Market Street, Level 3 Maidenhead Berkshire United Kingdom SL6 8AA | 2 | 0 | FOCLIVIA | No marketed DIN |
| AVENTIS PASTEUR INC. | 1 | 0 | FLUZONE TRIVALENT WHOLE VIRION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 15 MCG / 0.5 ML |
|---|---|
| Dosage form | SUSPENSION |
| Route | SUBCUTANEOUS ; INTRAMUSCULAR |
| Pack configuration (monograph) | 0.5 mL pre-filled single-dose syringes (glass, type I) with or without a needle. Available in packs of 1 or 10. |
| Storage | Not explicitly detailed in the provided text (section 11 header present but content missing), though standard vaccine handling is implied. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Influenza, Inactivated, Split Virus Or Surface Antigen |
|---|---|
| ATC code | J07BB02 |
| AHFS class | 80:12.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02484854 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2484854 |
| Brand name | INFLUVAC TETRA |
| Generic / active ingredient | HAEMAGGLUTININ-STRAIN A (H1N1) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN B (YAMAGATA) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN B (VICTORIA) : 15 MCG / 0.5 ML HAEMAGGLUTININ-STRAIN A (H3N2) : 15 MCG / 0.5 ML |
| Market authorization holder | BGP PHARMA ULC |
| Health Canada schedule | Schedule D |
| ATC code | J07BB02 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J07BB |
| Current status | MARKETED |
| Status date | 17-Oct-2019 |
| Original market date | 2019-10-17 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults and children ≥6 months: 0.5 mL. Unprimed children <9 years: second 0.5 mL dose after ≥4 weeks. Administer by IM or deep SC injection. Shake well before use.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to active substances, eggs, chicken protein, formaldehyde, cetyltrimethylammonium bromide, polysorbate 80, or gentamicin. Defer in presence of febrile illness or acute infection.
Warnings and precautions
Do not use if allergic to eggs or vaccine components. Not for intravascular use. Potential for anaphylaxis; keep epinephrine available. Risk of GBS if occurred within 6 weeks of previous flu vaccine.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
8 of 36 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AREPANRIX H5N1 | 3.75 MCG / 0.5 ML | EMULSION | ID BIOMEDICAL CORPORATION OF QUEBEC | MARKETED | 02401886 |
| FLUAD | 15 MCG / 0.5 ML | SUSPENSION | SEQIRUS UK LIMITED | MARKETED | 02362384 |
| FLUCELVAX | 15 MCG / 0.5 ML | SUSPENSION | SEQIRUS UK LIMITED | MARKETED | 02553708 |
| FLUVIRAL | 15 MCG / 0.5 ML | SUSPENSION | ID BIOMEDICAL CORPORATION OF QUEBEC | MARKETED | 02420686 |
| FLUZONE | 15 MCG / 0.5 ML | SUSPENSION | SANOFI PASTEUR LIMITED | MARKETED | 02365936 |
| FLUZONE | 15 MCG / 0.5 ML | SUSPENSION | SANOFI PASTEUR LIMITED | MARKETED | 02365707 |
| FLUZONE HIGH-DOSE | 60 MCG / 0.5 ML | SUSPENSION | SANOFI PASTEUR LIMITED | MARKETED | 02445646 |
| AFLURIA TETRA | 15 MCG / 0.5 ML | SUSPENSION | SEQIRUS PTY LTD | CANCELLED POST MARKET | 02473283 |
| AFLURIA TETRA | 15 MCG / 0.5 ML | SUSPENSION | SEQIRUS PTY LTD | CANCELLED POST MARKET | 02473313 |
| AGRIFLU | 15 MCG / 0.5 ML | SUSPENSION | SEQIRUS UK LIMITED | CANCELLED PRE MARKET | 02346850 |
2 · Same class — other molecules in ATC J07BB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Influenza, Inactivated, Split Virus Or Surface Antigen | AFLURIA TETRA · AGRIFLU · AREPANRIX H5N1 · FLUAD · +18 more | 36 | 8 | Yes |
| Influenza, Inactivated, Whole Virus | FLUVIRAL · INFLUVAC | 3 | 1 | Yes |
| Influenza, Live Attenuated | FLUMIST · FLUMIST QUADRIVALENT | 2 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J07B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J07BC | Combinations · Hepatitis A, Inactivated, Whole Virus · Hepatitis B, Purified Antigen | 19 | 9 |
| J07BN | Covid-19, Protein Subunit · Covid-19, Rna-Based Vaccine · Covid-19, Viral Vector, Non-Replicating | 28 | 5 |
| J07BD | Measles, Combin. With Mumps And Rubella, Live Attenuated · Measles, Combinations With Mumps, Rubella And Varicella, Live Attenuated · Morbilli, Comb. With Rubella, Live Attenuated · Morbilli, Live Attenuated | 8 | 4 |
| J07BX | Chikungunya Vaccines · Ebola Vaccines · Other Viral Vaccines · Respiratory Syncytial Virus Vaccine · Smallpox And Monkeypox Vaccines | 9 | 4 |
| J07BK | Varicella Zoster Vaccines · Varicella, Live Attenuated · Zoster, Live Attenuated | 7 | 3 |
| J07BH | Rota Virus, Live Attenuated · Rota Virus, Pentavalent, Live, Reassorted | 2 | 2 |
| J07BG | Rabies, Inactivated, Whole Virus | 3 | 2 |
| J07BM | Papillomavirus (Human Types 16,18) · Papillomavirus (Human Types 6,11,16,18,31,33,45,52,58) · Papillomavirus (Human Types 6,11,16,18) | 3 | 2 |
4 · Fixed-dose combinations with Canadian supply
| Product | Active ingredients | Holder | Status | DIN |
|---|---|---|---|---|
| AVAXIM | HEPATITIS A VIRUS, INACTIVATED : 160 UNIT / 0.5 ML | SANOFI PASTEUR LIMITED | MARKETED | 02237792 |
| COMIRNATY | *SARSCOV2 S-PROTEIN MRNA, 5'[M27,3'-OGPPP(M12'-O)APG], 3'POLYA+LINKER : 30 MCG / 0.3 ML | BIONTECH MANUFACTURING GMBH | MARKETED | 02552035 |
| HAVRIX 1440 | HEPATITIS A VIRUS, INACTIVATED : 1440 UNIT | GLAXOSMITHKLINE INC | MARKETED | 02187078 |
| HAVRIX 720 JUNIOR | HEPATITIS A VIRUS, INACTIVATED : 720 UNIT / 0.5 ML | GLAXOSMITHKLINE INC | MARKETED | 02231056 |
| MRESVIA | *RSV F-PROTEIN MRNA, 5'(M7G-5'-PPP-5'-GM), 3'POLYA : 50 MCG / 0.5 ML | MODERNA BIOPHARMA CANADA CORPORATION | MARKETED | 02552914 |
| ROTARIX | ROTAVIRUS VACCINE (RIX4414 STRAIN), LIVE, ORAL, ATTENUATED (HUMAN) : 1000000 CCID50 / 1.5 ML | GLAXOSMITHKLINE INC | MARKETED | 02300591 |
| SPIKEVAX | *SARSCOV2 S-PROTEIN MRNA, 5'(M7G-5'-PPP-5'-GM), 3'POLYA : 0.1 MG | MODERNA BIOPHARMA CANADA CORPORATION | MARKETED | 02541270 |
| TWINRIX | HEPATITIS B SURFACE ANTIGEN (RECOMBINANT) : 20 MCG / 1 ML HEPATITIS A VIRUS, INACTIVATED : 720 UNIT / 1 ML | GLAXOSMITHKLINE INC | MARKETED | 02230578 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.